Lisata Therapeutics, Inc.
LSTA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1 |
| % Growth | -100% | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $1 |
| % Margin | – | 100% | – | 100% |
| R&D Expenses | $2 | $2 | $3 | $3 |
| G&A Expenses | $2 | $3 | $3 | $3 |
| SG&A Expenses | $2 | $3 | $3 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4 | $5 | $6 | $6 |
| Operating Income | -$4 | -$5 | -$6 | -$5 |
| % Margin | – | -6,954.3% | – | -494.9% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$4 | -$5 | -$6 | -$5 |
| Tax Expense | $0 | $0 | -$1 | $0 |
| Net Income | -$4 | -$5 | -$5 | -$5 |
| % Margin | – | -6,655.7% | – | -461% |
| EPS | -0.49 | -0.54 | -0.55 | -0.55 |
| % Growth | 9.3% | 1.8% | 0% | – |
| EPS Diluted | -0.49 | -0.54 | -0.55 | -0.55 |
| Weighted Avg Shares Out | 9 | 9 | 9 | 8 |
| Weighted Avg Shares Out Dil | 9 | 9 | 9 | 8 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | -$5 | -$6 | -$5 |
| % Margin | – | -6,592.9% | – | -490.8% |